-- / 20 shares
₹ 1550.59 Cr
Retail Gain/Listing Gain
Concord Biotech Ltd. is an Indian biopharmaceutical company, holding a prominent position among global developers and manufacturers (in terms of volume in 2022) of fermentation-based APIs. These Active Pharmaceutical Ingredients known as APIs, play a crucial role in preventing or curing diseases (Source: F&S Report).
The company also holds a market share of over 20% by volume in 2022, across fermentation-based API products, including mupirocin, sirolimus, tacrolimus, mycophenolate sodium and cyclosporine.
Concord Biotech supplies to over 70 countries including regulated markets, such as the United States, Europe, Japan, and India. In 2016, the company launched its formulation business in India as well as emerging markets, including Nepal, Mexico, Indonesia, Thailand, Ecuador, Kenya, Singapore and Paraguay, and have further expanded in the United States.
With that, let's take a look at the competitive strengths and risks factors for Concord Biotech Ltd:
Delays in the supply and transport of raw materials may adversely impact the pricing and supply of end products, thus adversely affecting the business.
The company's reputation could be at risk if there are any manufacturing or quality control issues, potentially resulting in a decline in brand prominence.
Any slowdown or shutdown of its research and development operations can adversely affect the business.
Continue to increase the API market share and further develop the product portfolio.
Increase the presence of existing formulations and expand into new formulations.
Grow the CDMO business.
Here are the key financials for Concord Biotech Limited.
Particulars (in Rs. million)
How to apply for IPO through ASBA
00m 58 s
The Concord Biotech Limited IPO has an issue size of Rs. 1,550.52 crores. The IPO opens for subscription on 4th August and ends on 8th August.
Link Intime India Private Limited is the registrar for this IPO.